Cover Image

Cost-Effectiveness of Pembrolizumab Plus Chemotherapy Versus Pembrolizumab Monotherapy in Metastatic Non-Squamous and Squamous NSCLC Patients With PD-L1 Expression ≥ 50%

Objective To compare the cost-effectiveness of the combination of pembrolizumab and chemotherapy (Pembro+Chemo) versus pembrolizumab monotherapy (Pembro) as the first-line treatment for metastatic non-squamous and squamous non-small-cell lung cancer (NSCLC) with PD-L1expression ≥50%, respectively, f...

Full description

Saved in:

Bibliographic Details
Main Authors:	Qiao Liu (Author), Zhen Zhou (Author), Xia Luo (Author), Lidan Yi (Author), Liubao Peng (Author), Xiaomin Wan (Author), Chongqing Tan (Author), Xiaohui Zeng (Author)
Format:	Book
Published:	Frontiers Media S.A., 2022-01-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Economic evaluation of sintilimab plus chemotherapy vs. pembrolizumab plus chemotherapy for the treatment of first-line advanced or metastatic squamous NSCLC
by: Pingyu Chen, et al.
Published: (2022)

Cost-Effectiveness of Pembrolizumab Plus Chemotherapy as First-Line Therapy for Advanced Oesophageal Cancer
by: Meiyu Wu, et al.
Published: (2022)

First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis
by: Qiao Liu, et al.
Published: (2021)

Cost-Effectiveness Analysis of Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer in China
by: Zhang X, et al.
Published: (2023)

Cost-Effectiveness Analysis of Pembrolizumab Plus Chemotherapy vs. Chemotherapy Alone as First-Line Treatment in Patients With Esophageal Squamous Cell Carcinoma and PD-L1 CPS of 10 or More
by: Zhiwei Zheng, et al.
Published: (2022)

Prolonged Response to Pembrolizumab in Spindle Cell Squamous Cell Carcinoma Metastatic to the Central Nervous System
by: Yuxin Liu MD, et al.
Published: (2019)

Cost-Effectiveness of First-Line Versus Second-Line Pembrolizumab or Chemotherapy in Patients With Microsatellite-Instability-High/Mismatch Repair-Deficient Advanced Colorectal Cancer
by: Tan Chongqing, et al.
Published: (2021)

Good Response of Advanced Thymic Carcinoma with Low PD-L1 Expression to Chemotherapy plus Pembrolizumab as First-Line Therapy and to Pembrolizumab as Maintenance Therapy: A Case Report
by: Yoichi Nishii, et al.
Published: (2022)

Rare case of chemotherapy-refractory metastatic vaginal squamous cell carcinoma with complete response to concurrent pembrolizumab and radiotherapy- case report and literature review
by: Jawaher Ansari, et al.
Published: (2021)

Pembrolizumab and Chemotherapy Combination Prolonged Progression-Free Survival in Patients with NSCLC with High PD-L1 Expression and Low Neutrophil-to-Lymphocyte Ratio
by: Jeng-Shiuan Tsai, et al.
Published: (2022)

Advanced Merkel cell carcinoma in setting of pembrolizumab therapy for squamous cell carcinoma
by: Henry Jeon, BSc, et al.
Published: (2024)

Health-Related Quality of Life with Pembrolizumab in Patients with Locally Advanced or Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: KEYNOTE-629
by: Åse Bratland, et al.
Published: (2023)

Near complete response to a pembrolizumab-based therapeutic strategy in an abdominal metastatic head and neck squamous cell carcinoma case
by: Taowei Wu, et al.
Published: (2022)

Regression of cutaneous squamous cell carcinoma after the development of pembrolizumab‐induced bullous pemphigoid
by: Shin Iinuma, et al.
Published: (2023)

Tumor molecular profiling of responders and non-responders following pembrolizumab monotherapy in chemotherapy resistant advanced cervical cancer
by: N.Y.L. Ngoi, et al.
Published: (2018)

Complete response of metastatic cutaneous squamous cell carcinoma and multiple locally advanced basal cell carcinomas with concomitant pembrolizumab and sonidegib therapy
by: Carlos González-Cruz, MD, et al.
Published: (2024)

Cost-effectiveness analysis of camrelizumab plus chemotherapy as first-line treatment for advanced squamous NSCLC in China
by: Taihang Shao, et al.
Published: (2022)

Profile of pembrolizumab in the treatment of head and neck squamous cell carcinoma: design development and place in therapy
by: Haque S, et al.
Published: (2017)

Activity of pembrolizumab and lenvatinib in mismatch repair deficient (dMMR) endometrial cancer patients who have failed pembrolizumab monotherapy: A case series
by: Peter G. Rose, et al.
Published: (2023)

Lenvatinib plus pembrolizumab in patients with advanced or recurrent uterine carcinosarcoma
by: Jonathan T. Hunt, et al.
Published: (2021)

An extrauterine extensively metastatic epithelioid trophoblastic tumor responsive to pembrolizumab
by: Sarah G. Bell, et al.
Published: (2021)

Lichen planopilaris associated with pembrolizumab in a patient with metastatic melanoma
by: Anna L. Cogen, MD, PhD, et al.
Published: (2018)

Metastatic porocarcinoma: A case demonstrating objective response to pembrolizumab
by: Camélia Benhayoun, et al.
Published: (2024)

Nivolumab plus ipilimumab with chemotherapy in metastatic NSCLC: minireview and a case study of a patient negative for PD-L1
by: Alessandro Morabito
Published: (2024)

Cost-effectiveness of pembrolizumab plus chemotherapy vs. chemotherapy as first-line treatment for advanced biliary tract cancer in China and the US
by: Xianmei Luo, et al.
Published: (2024)

Lenvatinib Plus Pembrolizumab vs. Chemotherapy in Pretreated Patients With Advanced Endometrial Cancer: A Cost-Effectiveness Analysis
by: Mingyang Feng, et al.
Published: (2022)

The efficacy and safety of lenvatinib plus pembrolizumab therapy in patients with uterine carcinosarcoma
by: Risako Ozawa, et al.
Published: (2024)

Maintenance Therapy with Pembrolizumab after Platinum-Doublet Chemotherapy Leading to Hyperprogression in a Patient with Metastatic Bladder Cancer
by: Yangchun Gu, et al.
Published: (2021)

Case report: Clinical experience of treating pembrolizumab-induced systemic capillary leak syndrome (SCLS) in one patient with metastatic gastroesophageal junction squamous cell carcinoma
by: Hua Ni, et al.
Published: (2023)

Successful treatment of squamous cell carcinoma arising from a presumed ovarian mature cystic teratoma with pembrolizumab
by: Meng Wu, et al.
Published: (2021)

Response to lenvatinib and pembrolizumab combination therapy in pembrolizumab-pretreated relapsed endometrial cancer
by: Kaito Mimura, et al.
Published: (2022)

Stevens-Johnson Syndrome and Severe Anaemia: A Case of Toxicity Induced by Vemurafenib plus Cobimetinib following Pembrolizumab for Metastatic Melanoma
by: Tanja Batinac, et al.
Published: (2022)

Pembrolizumab and lenvatinib in recurrent ovarian clear cell carcinoma resistant to chemotherapy
by: Blair McNamara, et al.
Published: (2023)

Coincident Metastatic Melanoma and Merkel Cell Carcinoma with Complete Remission on Treatment with Pembrolizumab
by: Alexander Thiem, et al.
Published: (2017)

Overall survival in metastatic melanoma correlates with pembrolizumab exposure and T cell exhaustion markers
by: Vishal Navani, et al.
Published: (2021)

Tislelizumab plus chemotherapy versus pembrolizumab plus chemotherapy for the first-line treatment of advanced non-small cell lung cancer: systematic review and indirect comparison of randomized trials
by: Yimeng Guo, et al.
Published: (2023)

Cost-Effectiveness of Bevacizumab Biosimilar LY01008 Combined With Chemotherapy as First-Line Treatment for Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small Cell Lung Cancer
by: Xia Luo, et al.
Published: (2022)

Pembrolizumab-induced lichen planus pemphigoides in a patient with metastatic Merkel cell carcinoma
by: Chase W. Kwon, MD, et al.
Published: (2020)

Metastatic melanoma with features of blue nevus and tumoral melanosis identified during pembrolizumab therapy
by: Matthew F. Helm, MD, et al.
Published: (2017)

Effectiveness and safety of atezolizumab, nivolumab and pembrolizumab in metastatic non-small cell lung cancer
by: Amparo Burgos-San José, et al.
Published: (2021)